Fundraising Fox
Travere Therapeutics
NASDAQ: TVTX1 known investors
Find your way into Travere Therapeutics
Sign up to see every warm intro you have to Travere Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Travere Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Travere Therapeutics develops and delivers therapies for rare kidney and metabolic diseases, with a pipeline including potential first-in-class treatments for conditions such as classical homocystinuria and immune-mediated rare kidney diseases. The company also supports initiatives to improve diagnosis, access, and equity in rare disease care for patients and their families.
Founders & leadership
Investors · 1
Frequently asked questions
- What does Travere Therapeutics do?
- Travere Therapeutics develops and delivers therapies for rare kidney and metabolic diseases, with a pipeline including potential first-in-class treatments for conditions such as classical homocystinuria and immune-mediated rare kidney diseases. The company also supports initiatives to improve diagnosis, access, and equity in rare disease care for patients and their families.
- Who are Travere Therapeutics's investors?
- Travere Therapeutics's investors include Ligand Pharmaceuticals.